results: our analyses indicated a significantly higher rate of total and specific treatment-emergent sd and specific phases of dysfunction compared with placebo for the following drugs in decreasing order of impact: sertraline, venlafaxine, citalopram, paroxetine, fluoxetine, imipramine, phenelzine, duloxetine, escitalopram, and fluvoxamine, with sd ranging from 25.8% to 80.3% of patients.